Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma

Joan Admirand, George Z. Rassidakis, Lynne V. Abruzzo, Jose R. Valbuena, Dan Jones, L. Jeffrey Medeiros

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Using immunohistochemical methods, we evaluated zeta-associated protein (ZAP)-70 expression in 341 cases of non-Hodgkin and Hodgkin lymphoma. In B-cell NHL, ZAP-70 was positive in five of six (83%) precursor B-lymphoblastic lymphoma, 11 of 37 (30%) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), five of 39 (13%) mantle cell lymphoma, one of 12 (8%) Burkitt lymphoma, and one of 12 (8%) nodal marginal zone B-cell lymphoma. In 22 cases of CLL/SLL, seven of nine (78%) with unmutated IgVH genes expressed ZAP-70, compared with one of 13 (8%) with mutated IgVH genes (P=0.0015 Fisher's exact test). ZAP-70 expression was not detected in diffuse large B-cell lymphoma (n=26), extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (n=24), follicular lymphoma (n=21), plasma cell myeloma/plasmacytoma (n=10), lymphoplasmacytic lymphoma (n=10), or splenic marginal zone lymphoma (n=6). In T/NK-cell NHL, ZAP-70 was positive in all extranodal natural killer (NK)/T-cell lymphoma, nasal-type (n=6) and enteropathy-type T-cell lymphoma (n=4), four of five (80%) subcutaneous panniculitis-like T-cell lymphoma, six of eight (75%) mycosis fungoides, three of five (60%) precursor T-lymphoblastic lymphoma, 10 of 17 (59%) peripheral T-cell lymphoma, two of four (50%) blastic NK-cell lymphoma, one of three (33%) T-cell prolymphocytic leukemia, 13 of 52 (25%) anaplastic large cell lymphoma, and one of six (17%) angioimmunoblastic T-cell lymphoma. Seven of 12 (58%) cutaneous CD30-positive lymphoproliferative disorders were also ZAP-70-positive. In Hodgkin lymphoma, ZAP-70 was negative in neoplastic cells in all cases tested. ZAP-70 staining in B-cell lymphomas and reactive T cells was predominantly nuclear with variable cytoplasmic staining. By contrast, ZAP-70 staining in T/NK-cell lymphomas was heterogeneous, and a shift from predominantly nuclear to predominantly cytoplasmic staining was observed, particularly in those neoplasms with high-grade morphology. In summary, ZAP-70 is expressed by many lymphoma types, correlates with immunoglobulin heavy-chain variable region gene mutational status in CLL/SLL, and can be detected reliably using immunohistochemical methods.

Original languageEnglish (US)
Pages (from-to)954-961
Number of pages8
JournalModern Pathology
Volume17
Issue number8
DOIs
StatePublished - Aug 1 2004

Fingerprint

Hodgkin Disease
Non-Hodgkin's Lymphoma
B-Cell Chronic Lymphocytic Leukemia
Lymphoma
Proteins
Marginal Zone B-Cell Lymphoma
Natural Killer T-Cells
T-Cell Lymphoma
Staining and Labeling
Precursor Cell Lymphoblastic Leukemia-Lymphoma
T-Cell Prolymphocytic Leukemia
Genes
Peripheral T-Cell Lymphoma
Anaplastic Large-Cell Lymphoma
Mantle-Cell Lymphoma
Immunoglobulin Heavy Chains
Mycosis Fungoides
Follicular Lymphoma
Plasmacytoma
Burkitt Lymphoma

Keywords

  • Chronic lymphocytic leukemia/small lymphocytic lymphoma
  • Hodgkin lymphoma
  • Immunohistochemistry
  • Non-Hodgkin lymphoma
  • ZAP-70

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Admirand, J., Rassidakis, G. Z., Abruzzo, L. V., Valbuena, J. R., Jones, D., & Medeiros, L. J. (2004). Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma. Modern Pathology, 17(8), 954-961. https://doi.org/10.1038/modpathol.3800145

Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma. / Admirand, Joan; Rassidakis, George Z.; Abruzzo, Lynne V.; Valbuena, Jose R.; Jones, Dan; Medeiros, L. Jeffrey.

In: Modern Pathology, Vol. 17, No. 8, 01.08.2004, p. 954-961.

Research output: Contribution to journalArticle

Admirand, J, Rassidakis, GZ, Abruzzo, LV, Valbuena, JR, Jones, D & Medeiros, LJ 2004, 'Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma', Modern Pathology, vol. 17, no. 8, pp. 954-961. https://doi.org/10.1038/modpathol.3800145
Admirand, Joan ; Rassidakis, George Z. ; Abruzzo, Lynne V. ; Valbuena, Jose R. ; Jones, Dan ; Medeiros, L. Jeffrey. / Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma. In: Modern Pathology. 2004 ; Vol. 17, No. 8. pp. 954-961.
@article{d585d6b1a41847fa911b21b5daeded2d,
title = "Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma",
abstract = "Using immunohistochemical methods, we evaluated zeta-associated protein (ZAP)-70 expression in 341 cases of non-Hodgkin and Hodgkin lymphoma. In B-cell NHL, ZAP-70 was positive in five of six (83{\%}) precursor B-lymphoblastic lymphoma, 11 of 37 (30{\%}) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), five of 39 (13{\%}) mantle cell lymphoma, one of 12 (8{\%}) Burkitt lymphoma, and one of 12 (8{\%}) nodal marginal zone B-cell lymphoma. In 22 cases of CLL/SLL, seven of nine (78{\%}) with unmutated IgVH genes expressed ZAP-70, compared with one of 13 (8{\%}) with mutated IgVH genes (P=0.0015 Fisher's exact test). ZAP-70 expression was not detected in diffuse large B-cell lymphoma (n=26), extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (n=24), follicular lymphoma (n=21), plasma cell myeloma/plasmacytoma (n=10), lymphoplasmacytic lymphoma (n=10), or splenic marginal zone lymphoma (n=6). In T/NK-cell NHL, ZAP-70 was positive in all extranodal natural killer (NK)/T-cell lymphoma, nasal-type (n=6) and enteropathy-type T-cell lymphoma (n=4), four of five (80{\%}) subcutaneous panniculitis-like T-cell lymphoma, six of eight (75{\%}) mycosis fungoides, three of five (60{\%}) precursor T-lymphoblastic lymphoma, 10 of 17 (59{\%}) peripheral T-cell lymphoma, two of four (50{\%}) blastic NK-cell lymphoma, one of three (33{\%}) T-cell prolymphocytic leukemia, 13 of 52 (25{\%}) anaplastic large cell lymphoma, and one of six (17{\%}) angioimmunoblastic T-cell lymphoma. Seven of 12 (58{\%}) cutaneous CD30-positive lymphoproliferative disorders were also ZAP-70-positive. In Hodgkin lymphoma, ZAP-70 was negative in neoplastic cells in all cases tested. ZAP-70 staining in B-cell lymphomas and reactive T cells was predominantly nuclear with variable cytoplasmic staining. By contrast, ZAP-70 staining in T/NK-cell lymphomas was heterogeneous, and a shift from predominantly nuclear to predominantly cytoplasmic staining was observed, particularly in those neoplasms with high-grade morphology. In summary, ZAP-70 is expressed by many lymphoma types, correlates with immunoglobulin heavy-chain variable region gene mutational status in CLL/SLL, and can be detected reliably using immunohistochemical methods.",
keywords = "Chronic lymphocytic leukemia/small lymphocytic lymphoma, Hodgkin lymphoma, Immunohistochemistry, Non-Hodgkin lymphoma, ZAP-70",
author = "Joan Admirand and Rassidakis, {George Z.} and Abruzzo, {Lynne V.} and Valbuena, {Jose R.} and Dan Jones and Medeiros, {L. Jeffrey}",
year = "2004",
month = "8",
day = "1",
doi = "10.1038/modpathol.3800145",
language = "English (US)",
volume = "17",
pages = "954--961",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma

AU - Admirand, Joan

AU - Rassidakis, George Z.

AU - Abruzzo, Lynne V.

AU - Valbuena, Jose R.

AU - Jones, Dan

AU - Medeiros, L. Jeffrey

PY - 2004/8/1

Y1 - 2004/8/1

N2 - Using immunohistochemical methods, we evaluated zeta-associated protein (ZAP)-70 expression in 341 cases of non-Hodgkin and Hodgkin lymphoma. In B-cell NHL, ZAP-70 was positive in five of six (83%) precursor B-lymphoblastic lymphoma, 11 of 37 (30%) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), five of 39 (13%) mantle cell lymphoma, one of 12 (8%) Burkitt lymphoma, and one of 12 (8%) nodal marginal zone B-cell lymphoma. In 22 cases of CLL/SLL, seven of nine (78%) with unmutated IgVH genes expressed ZAP-70, compared with one of 13 (8%) with mutated IgVH genes (P=0.0015 Fisher's exact test). ZAP-70 expression was not detected in diffuse large B-cell lymphoma (n=26), extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (n=24), follicular lymphoma (n=21), plasma cell myeloma/plasmacytoma (n=10), lymphoplasmacytic lymphoma (n=10), or splenic marginal zone lymphoma (n=6). In T/NK-cell NHL, ZAP-70 was positive in all extranodal natural killer (NK)/T-cell lymphoma, nasal-type (n=6) and enteropathy-type T-cell lymphoma (n=4), four of five (80%) subcutaneous panniculitis-like T-cell lymphoma, six of eight (75%) mycosis fungoides, three of five (60%) precursor T-lymphoblastic lymphoma, 10 of 17 (59%) peripheral T-cell lymphoma, two of four (50%) blastic NK-cell lymphoma, one of three (33%) T-cell prolymphocytic leukemia, 13 of 52 (25%) anaplastic large cell lymphoma, and one of six (17%) angioimmunoblastic T-cell lymphoma. Seven of 12 (58%) cutaneous CD30-positive lymphoproliferative disorders were also ZAP-70-positive. In Hodgkin lymphoma, ZAP-70 was negative in neoplastic cells in all cases tested. ZAP-70 staining in B-cell lymphomas and reactive T cells was predominantly nuclear with variable cytoplasmic staining. By contrast, ZAP-70 staining in T/NK-cell lymphomas was heterogeneous, and a shift from predominantly nuclear to predominantly cytoplasmic staining was observed, particularly in those neoplasms with high-grade morphology. In summary, ZAP-70 is expressed by many lymphoma types, correlates with immunoglobulin heavy-chain variable region gene mutational status in CLL/SLL, and can be detected reliably using immunohistochemical methods.

AB - Using immunohistochemical methods, we evaluated zeta-associated protein (ZAP)-70 expression in 341 cases of non-Hodgkin and Hodgkin lymphoma. In B-cell NHL, ZAP-70 was positive in five of six (83%) precursor B-lymphoblastic lymphoma, 11 of 37 (30%) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), five of 39 (13%) mantle cell lymphoma, one of 12 (8%) Burkitt lymphoma, and one of 12 (8%) nodal marginal zone B-cell lymphoma. In 22 cases of CLL/SLL, seven of nine (78%) with unmutated IgVH genes expressed ZAP-70, compared with one of 13 (8%) with mutated IgVH genes (P=0.0015 Fisher's exact test). ZAP-70 expression was not detected in diffuse large B-cell lymphoma (n=26), extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (n=24), follicular lymphoma (n=21), plasma cell myeloma/plasmacytoma (n=10), lymphoplasmacytic lymphoma (n=10), or splenic marginal zone lymphoma (n=6). In T/NK-cell NHL, ZAP-70 was positive in all extranodal natural killer (NK)/T-cell lymphoma, nasal-type (n=6) and enteropathy-type T-cell lymphoma (n=4), four of five (80%) subcutaneous panniculitis-like T-cell lymphoma, six of eight (75%) mycosis fungoides, three of five (60%) precursor T-lymphoblastic lymphoma, 10 of 17 (59%) peripheral T-cell lymphoma, two of four (50%) blastic NK-cell lymphoma, one of three (33%) T-cell prolymphocytic leukemia, 13 of 52 (25%) anaplastic large cell lymphoma, and one of six (17%) angioimmunoblastic T-cell lymphoma. Seven of 12 (58%) cutaneous CD30-positive lymphoproliferative disorders were also ZAP-70-positive. In Hodgkin lymphoma, ZAP-70 was negative in neoplastic cells in all cases tested. ZAP-70 staining in B-cell lymphomas and reactive T cells was predominantly nuclear with variable cytoplasmic staining. By contrast, ZAP-70 staining in T/NK-cell lymphomas was heterogeneous, and a shift from predominantly nuclear to predominantly cytoplasmic staining was observed, particularly in those neoplasms with high-grade morphology. In summary, ZAP-70 is expressed by many lymphoma types, correlates with immunoglobulin heavy-chain variable region gene mutational status in CLL/SLL, and can be detected reliably using immunohistochemical methods.

KW - Chronic lymphocytic leukemia/small lymphocytic lymphoma

KW - Hodgkin lymphoma

KW - Immunohistochemistry

KW - Non-Hodgkin lymphoma

KW - ZAP-70

UR - http://www.scopus.com/inward/record.url?scp=3342912150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3342912150&partnerID=8YFLogxK

U2 - 10.1038/modpathol.3800145

DO - 10.1038/modpathol.3800145

M3 - Article

VL - 17

SP - 954

EP - 961

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 8

ER -